SCAI-001 not checked
SCAI Therapeutics · Cyclosporine 0.01% · Cyclosporine 0.02%
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Dry Eye Syndromes
- Main trialPhase 2
- “This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.”In the company’s words, NCT05733624 on ClinicalTrials.gov
- Other names
- Cyclosporine 0.01% · Cyclosporine 0.02%
- Copy of
- Restasis (Allergan)Tested side by side with the original in NCT05733624
Other drugs for Dry Eye Syndromes
- LicaminlimabOculis · Phase 2/3
- NipocalimabJohnson & Johnson (Janssen) · Phase 3
- VVN001VivaVision Biotech, Inc · Phase 3
- CAM-101Cambium Bio Limited · Phase 3
- TelitaciceptVor Biopharma · Phase 3
- OT202Ocumension Therapeutics (Shanghai) Co., Ltd · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 23 Aug 2023 | Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026